石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

未开盘 05-27 16:09:08

2.300

-0.050

-2.13%

最高2.390	最低2.300	成交量181.00万
今开2.390	昨收2.350	日振幅3.83%
总市值66.49亿	流通市值66.49亿	总股本28.91亿
成交额419.28万	换手率0.06%	流通股本28.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.3,"timestamp":1779869348004,"preClose":2.35,"halted":0,"volume":1810000,"delay":0,"changeRate":-0.021276595744680965,"floatShares":2891000000,"shares":2891000000,"eps":0.1605,"marketStatus":"未开盘","change":-0.05,"latestTime":"05-27 16:09:08","open":2.39,"high":2.39,"low":2.3,"amount":4192820,"amplitude":0.038298,"askPrice":2.31,"askSize":160000,"bidPrice":2.3,"bidSize":174000,"shortable":3,"etf":0,"ttmEps":0.1605,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779931800000},"marketStatusCode":0,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.35,"dividendRate":0.034783,"openAndCloseTimeList":[[1779845400000,1779854400000],[1779858000000,1779868800000]],"volumeRatio":0.2843174008829053,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2638563176","title":"石四药集团(02005)：甲磺酸沙非胺获批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638563176","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638563176?lang=zh_cn&edition=full","pubTime":"2026-05-26 07:54","pubTimestamp":1779753270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团的甲磺酸沙非胺已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药，是国内企业首家获批。甲磺酸沙非胺主要用于治疗帕金森病，与左旋多巴等其他帕金森药物联合使用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381524","title":"石四药集团(02005)：美阿沙坦钾获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381524","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637381524?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:48","pubTimestamp":1779356924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的美阿沙坦钾已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。美阿沙坦钾主要用于治疗成人原发性高血压。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2460026573.USD","IPOS","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637223386","title":"石四药集团(02005)取得若干药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2637223386","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637223386?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:08","pubTimestamp":1779354525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布产品开发的最新进展：集团是国内第二家企业取得中国国家药监局有关富马酸依美斯汀滴眼液0.05%的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。集团是国内第三家企业取得国家药监局有关精氨酸培哚普利片的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。此产品主要用于治疗高血压与充血性心力衰竭。集团的布美他尼原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125608987","title":"石四药集团回购130万股股份，总额约308.47万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125608987","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125608987?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:35","pubTimestamp":1779352553,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年5月21日发布翌日披露报表，公告公司于同日通过香港联合交易所场内回购合计1,300,000股股份，约占当时公司已发行股份的0.045%。本次回购每股价格介乎港币2.36元至2.39元，合计付出约308.47万港元。公告显示，此次回购完成后，公司已发行股份降至2,891,443,385股，库存股份增至59,670,000股，合并计算后公司已发行股份总数维持在2,951,113,385股。本次交易完成后，任何新股发行或再次出售库存股份的相关操作将受暂定至2026年6月20日的时限约束。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购130万股股份，总额约308.47万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637858333","title":"石四药集团(02005)5月21日斥资308.47万港元回购130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637858333","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637858333?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:32","pubTimestamp":1779352368,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年5月21日，该公司斥资308.47万港元回购130万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136879891","title":"石四药集团5月20日回购200万股，耗资约462.66万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136879891","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136879891?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:36","pubTimestamp":1779266203,"startTime":"0","endTime":"0","summary":"石四药集团于2026年5月20日在香港联交所场内回购200万股普通股，占回购前公司已发行股份总数约0.069%。本次回购每股价格介于每股2.29港元至2.34港元之间，成交量加权平均价格约为每股2.3133港元，总耗资约462.66万港元。本次回购完成后，公司已发行股份数目为2,892,743,385股，新增库藏股份为2,000,000股，累计库藏股份数上升至58,370,000股。石四药集团同时确认，本次回购已遵守香港联合交易所有限公司证券上市规则及相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团5月20日回购200万股，耗资约462.66万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186654477","title":"石四药集团5月19日回购200万股，耗资约470.64万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186654477","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186654477?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:36","pubTimestamp":1779179800,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年5月19日发布公告，披露当日在香港联交所回购2,000,000股普通股，占回购前已发行股份约0.069%。本次回购价格区间为每股2.33港元至2.38港元，合计支付4,706,380港元。根据2026年5月15日通过的回购授权，公司可回购股份总数为289,924,338股，截至本次回购后，已累计回购4,500,000股，占该回购授权通过当日公司已发行股本的0.155%。公司在公告中确认，本次回购符合香港联交所上市规则及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团5月19日回购200万股，耗资约470.64万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636396648","title":"石四药集团(02005)5月19日斥资470.64万港元回购200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636396648","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636396648?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:35","pubTimestamp":1779179714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年5月19日该公司斥资470.64万港元回购200万股，回购价格为每股2.33-2.38港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163070939","title":"石四药集团：5月18日回购250万股，耗资约582.45万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163070939","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163070939?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:17","pubTimestamp":1779092223,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年5月18日公告，当日通过香港联交所场内回购普通股股份共计2,500,000股，占回购前公司已发行股本约0.086%。此次回购每股价格介乎港币2.30元至2.37元，合计支付约582.45万港元。本次回购完成后，公司已发行股本数量由2,899,243,385股减少至2,896,743,385股，库藏股数由51,870,000股增至54,370,000股。董事会于2026年5月15日通过相关回购授权，授权总回购股份数为289,924,338股，此次回购占该授权总数的2,500,000股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"497fd758b38c276bd0bec58e92fb66d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团：5月18日回购250万股，耗资约582.45万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636302310","title":"石四药集团(02005)5月18日斥资582.45万港元回购250万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636302310","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636302310?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:16","pubTimestamp":1779092205,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年5月18日斥资582.45万港元回购250万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"497fd758b38c276bd0bec58e92fb66d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634427333","title":"石四药集团(02005)获三药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2634427333","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634427333?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:16","pubTimestamp":1778458586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药品监督管理局有关磷酸奥司他韦胶囊的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。此产品主要用于各种病因所致恶心、呕吐症状的对症治疗、常规治疗无效的有症状的胃食管反流短期治疗，及急性和复发性糖尿病胃轻瘫症状的缓解。集团的甲氧氯普胺原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147933213","title":"石四药集团氰钴胺注射液1毫升:1毫克规格及一致性评价获中国批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1147933213","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147933213?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:34","pubTimestamp":1778142865,"startTime":"0","endTime":"0","summary":"中国药品监督管理部门已正式批准石四药集团（SSY Group）氰钴胺注射液的1毫升:1毫克规格及其一致性评价申请。该批准标志着该药物在特定剂量规格下的质量与疗效获得官方认可，为企业进一步拓展市场奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633116544","title":"石四药集团(02005)：维生素B12注射液已取得国家药监局批准增加1ml: 1mg规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2633116544","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633116544?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:34","pubTimestamp":1778142865,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的维生素B12注射液已取得中国国家药品监督管理局批准增加1ml: 1mg规格，同时获批准通过仿制药质量和疗效一致性评价，是国内企业第二家。维生素B12注射液主要用于因内因子缺乏所致的巨幼细胞性贫血，也可用于亚急性联合变性神经系统病变，如神经炎的辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：维生素B12注射液已取得国家药监局批准增加1ml: 1mg规格","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633164997","title":"港股公告掘金 | 东方证券拟通过发行A股股份及支付现金方式购买上海证券100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2633164997","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633164997?lang=zh_cn&edition=full","pubTime":"2026-05-07 09:00","pubTimestamp":1778115646,"startTime":"0","endTime":"0","summary":"重大事项：石四药集团(02005)取得甲磺酸多沙唑嗪缓释片(4mg)等药品的生产注册批件中国生物制药(01177)：库莫西利胶囊“CDK2/4/6抑制剂”一线治疗乳腺癌新适应症获批上市佰金生命科学(01466)附属与扶摇元气订立策略合作框架协议 开展临床细胞治疗领域的策略合作石四药集团(02005)：全量程C反应蛋白(hsCRP+常规CRP)检测试剂盒及血清淀粉样蛋白A/C反应蛋白(SAA/CRP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1227","HK0000165453.HKD","159982","VXUS","IE00BZ08YS42.EUR","BK0276","BK0188","BK4585","02005","BK1589","IE00BZ08YR35.GBP","BK0183","BK0028","01177","BK0012","BK1147","BK1564","03958","BK1521","BK1191","BK1515","BK4588","LU2460026573.USD","161027","399300","IE00BZ08YT58.USD","01466","600958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118440548","title":"石四药集团全量程C反应蛋白检测试剂盒等产品获河北省药监局医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1118440548","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118440548?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:50","pubTimestamp":1778057441,"startTime":"0","endTime":"0","summary":"石四药集团宣布，其全量程C反应蛋白检测试剂盒及其他配套试剂盒已正式获得河北省药品监督管理局颁发的医疗器械注册证书。这一重要资质的取得，标志着公司相关产品符合国家医疗器械市场准入标准，为后续商业化推广奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633970154","title":"石四药集团(02005)取得甲磺酸多沙唑嗪缓释片(4mg)等药品的生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2633970154","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633970154?lang=zh_cn&edition=full","pubTime":"2026-05-06 12:20","pubTimestamp":1778041210,"startTime":"0","endTime":"0","summary":"本集团已取得国家药监局有关甲磺酸多沙唑嗪缓释片的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。诚如本公司日期为2024年4月8日的公告所载，本集团的甲磺酸多沙唑嗪塬料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得甲磺酸多沙唑嗪缓释片(4mg)等药品的生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157696322","title":"石四药集团4月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1157696322","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157696322?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:39","pubTimestamp":1777883993,"startTime":"0","endTime":"0","summary":"2026年5月4日，石四药集团有限公司公布截至2026年4月30日止的股份变动月报表。报告显示，公司本月未发生新增发行、购回或注销股份等变动，整体股本保持稳定。根据公告，截至2026年4月30日，石四药集团法定注册股本为10,000,000,000股，面值每股港币0.02元，总额约为港币200,000,000，较上月保持不变。同时，公司于2023年1月13日采纳的二零二三年购股权计划对应的股份期权数量维持不变，本月底有最多297,268,338股可于未来行使。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632939901","title":"石四药集团(02005)一季度股东应占溢利约1.71亿港元 同比增加1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632939901","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632939901?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:38","pubTimestamp":1777883884,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布截至2026年一季度经营业绩，集团截至2026年3月31日止3个月的未经审核营业额约12.27亿港元，同比增加8.0%;毛利约5.02亿港元，同比减少1.3%，其未经审核毛利率约为41.0%，同比减少3.8百分点。截至2026年3月31日止3个月，集团的未经审核公司股东应占溢利约171,206,000港元，同比增加1.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630359103","title":"石四药集团(02005)取得国家药监局有关注射用盐酸地尔硫䓬(10mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2630359103","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630359103?lang=zh_cn&edition=full","pubTime":"2026-04-27 12:04","pubTimestamp":1777262692,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药监局有关注射用盐酸地尔硫的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。注射用盐酸地尔硫主要用于室上性心动过速、手术时异常高血压的急救处置、高血压急症及不稳定心绞痛。盐酸普萘洛尔注射液主要用于控制室上性快速心律失常及室性心律失常、劳力型心绞痛及嗜铬细胞瘤。集团的盐酸普萘洛尔原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得国家药监局有关注射用盐酸地尔硫䓬(10mg)的药品生产注册批件","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629308192","title":"石四药集团：2025年净利润4.71亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629308192","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629308192?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:02","pubTimestamp":1776762129,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月21日，石四药集团（02005.HK）公告，截至二零二五年十二月三十一日止年度，公司总收益为41.65亿港元，同比下降27.8%；年内溢利为4.71亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213712364659.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213712364659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0209},{"period":"3month","weight":-0.1241},{"period":"6month","weight":-0.2412},{"period":"1year","weight":-0.2107},{"period":"ytd","weight":-0.1768}],"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0399},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.0832},{"period":"ytd","weight":-0.0118}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008158},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020535},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079315},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030939},{"month":5,"riseRate":0.47619,"avgChangeRate":0.009905},{"month":6,"riseRate":0.5,"avgChangeRate":0.067887},{"month":7,"riseRate":0.35,"avgChangeRate":-0.027728},{"month":8,"riseRate":0.35,"avgChangeRate":-0.017719},{"month":9,"riseRate":0.3,"avgChangeRate":-0.046842},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001891},{"month":11,"riseRate":0.65,"avgChangeRate":0.086083},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009107}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}